Cardiovascular Catch-Up: Abbott, Medtronic, Boston Scientific Stay Hot During Summer
Executive Summary
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.
You may also be interested in...
Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market
The US FDA approved Aveir VR to treat significant bradycardia on 4 April. It is the world’s only leadless pacemaker with Abbott’s proprietary mapping capability that helps physicians correctly position the device inside the right ventricle.
JPM 2022: Abiomed, Penumbra, Renalityx
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.
Women May Face Additional Risks From LAAO Treatment, FDA Cautions
The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.